Search the evidence register: research titles, expert names and patent numbers

review · 2026

EHL BIO patents and research papers

EHL BIO (Republic of Korea)

EHL BIO publishes a list of patents and research papers in the R&D section of its corporate website. Readers should verify the current list at the source before citing.

phase3 · 2025

Randomised cell therapy studies in heart failure

Multiple institutions (indexed in PubMed)

Ejection fraction changes are small and inconsistent; some studies report reduced hospitalisation in high-inflammation subgroups.

phase1 · 2023

KDSTEM Inj.: Phase 1 trial in chronic kidney disease (hospital information)

EHL BIO (Korea)

The hospital's affiliated research centre states IND approval and Phase 1 initiation in 2023, with selection for the KFRM programme in 2022 and 2024. A Phase 1 trial targets safety, not proof of efficacy.

preclinical · 2024

Adipose-derived stem cell exosomes: animal testing (hospital information)

EHL BIO (Korea)

The hospital's affiliated research centre states animal testing for patent application, listing neuropathic pain, cartilage regeneration, wound healing, hypertension, Alzheimer's disease, retinopathy, Parkinson's disease and diabetes as indications under study.

phase1 · 2024

MSC in chronic kidney disease: early studies

International trial registries

Focused on safety and eGFR decline in small numbers of participants; no evidence of nephron regeneration.

phase1 · 2024

Early-stage MSC research in psoriasis

Case series and phase 1 studies

PASI reductions reported in small numbers of patients; must still be compared with far better-evidenced biologics.

phase1-2 · 2024

Intradiscal MSC injection

Multiple institutions (PubMed)

Acceptable safety and reduced pain scores in some groups; imaging changes remain inconsistent.

phase2 · 2024

ADSTEM Inj.: clinical trials in atopic dermatitis (hospital information)

EHL BIO with five Korean hospitals including Chung-Ang University Hospital (as stated by the hospital)

The hospital's affiliated research centre states Phase 1 completed in 2017, Phase 2 completed in 2023 and a Phase 3 IND submitted in 2024. No accessible peer-reviewed results confirm efficacy, and this is not approved treatment in Thailand.

preclinical · 2024

RASTEM Inj.: preclinical study in rheumatoid arthritis (hospital information)

EHL BIO (Korea)

The hospital's affiliated research centre states the non-clinical study is being completed and a clinical trial is in preparation. No human outcome data exist; patients should follow standard care such as methotrexate and biologics as prescribed.

preclinical · 2024

PDSTEM Inj.: preclinical study in Parkinson's disease (hospital information)

EHL BIO (Korea)

The hospital's affiliated research centre states the programme is at non-clinical stage, so there are no efficacy or safety data in people with Parkinson's disease, and it is not approved treatment.

phase1-2 · 2025

Exosome and secretome studies in hair loss

Multiple institutions (PubMed)

Some small studies report short-term increases in hair density, but preparations and endpoints vary widely and no large placebo-controlled trial exists.

phase1-2 · 2025

iPSC-derived dopaminergic neuron transplantation in Parkinson's disease

Specialised research centres in Japan and the United States

Reports procedural safety and graft survival in small numbers of participants; motor outcomes require long-term follow-up.

30 Apr 2022

Urine-Derived Stem Cell-Secreted Klotho Plays a Crucial Role in the HK-2 Fibrosis Model by Inhibiting the TGF-β Signaling Pathway

10 Dec 2023

In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application

21 Dec 2022

Production enhancement of human adipose-derived mesenchymal stem cells by low-intensity ultrasound stimulation

19 Nov 2016

Human adipose tissue derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation

6 Nov 2018

Human Adipose Tissue Derived Mesenchymal Stem Cells Attenuate Atopic Dermatitis by Regulating the Expression of MIP2, miR122a-SOCS1 Axis, and Th1/Th2 Responses

18 Jan 2024

Combinational Pulsing of TAAs Enforces Dendritic Cell-Based Immunotherapy through T-Cell Proliferation and Interferon-γ Secretion in LLC1 Mouse Model

Number not stated

Method for mass culturing adipose-derived stem cells expressing FoxO

Registered 28 Dec 2018

Related to a composition comprising cells treated with a 15-PGDH inhibitor or their culture and its use.

No. 10-2019-0139702

Medium composition for culturing urine-derived stem cells and method for culturing them

Registered 4 Nov 2019

Culture medium for isolating and culturing urine-derived stem cells, and a method for separating and culturing them using that medium.

No. 10-2020-0012437

Mass culture method of adipose-derived stem cells expressing anti-ageing factors

Registered 3 Feb 2020

Mass culture method for adipose-derived stem cells expressing Foxo1, Foxo3a and Klotho, with a medium composition for their proliferation and culture.

No. 10-2021-0021026

Composition for skin regeneration, whitening, antioxidant or wound treatment comprising stem cell-derived exosomes

Registered 17 Feb 2021

Cosmetic or pharmaceutical composition with urine-derived stem cell exosomes as the active ingredient.

No. 10-2021-0129299

Medium composition and method for isolating and culturing urine-derived stem cells with improved renal-disease function, and a cell therapeutic composition

Registered 29 Sept 2021

Covers the culture medium, the isolation and culture method, the resulting cells, and a cell therapeutic composition comprising them.

No. 10-2016-0007049

Liposuction and SVF separation kit

Registered 20 Jan 2016

Intended to facilitate fat collection and the series of processes for separating adipose-derived stem cells.

No. 15771853

Composition comprising cells treated with a 15-PGDH inhibitor or culture thereof and use thereof

Registered 27 Oct 2016

No. 10-2016-0139967

Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

Registered 26 Oct 2016

Pharmaceutical composition for preventing or treating atopic disease, using cells cultured with a 15-PGDH inhibitor in PGE2-expressing cells or their culture (atopic dermatitis).

No. 10-2018-0001149

Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

Registered 4 Jan 2018

Same family of pharmaceutical composition, with the indication stated as rheumatoid arthritis.

No. 10-2018-0030906

Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

Registered 16 Mar 2018

Pharmaceutical composition for preventing or treating atopic disease (atopic dermatitis).

EHL BIO

EHL BIO Stem Cell Research Institute

Stem cell therapeutics research and development team

ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes

EHL BIO

EHL BIO GMP Centre Quality Team

Manufacturing, quality control and cell banking

Class 100 clean facilities, cell banking systems and pre/post-cryopreservation quality control

EHL Thailand

EHL Thailand Medical Information Team

Writes and reviews disease pages and stem cell topics

Evidence levels, regulatory status, and separating hospital information from medical information

EHL BIO

MD Hong-gi Lee (CEO)

Chief Executive Officer, EHLBIO Co., Ltd.

Direction of stem cell, immune cell and exosome therapeutics development

EHL BIO

EHL BIO Immune Cell Research Team

Immune cell therapy research and immune cell banking

Keycell-IM programme (T, NK, iNKT and dendritic cells); the hospital's affiliated research centre states lung cancer as the preclinical target

EHL Thailand

EHL Thailand Research Desk

Reviews articles, research summaries and clinical trial status

Careful reading of study results, including sample size, trial phase and limitations